Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06908694 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Investigation of GLP1-Receptor Agonists in Men With Prostate Cancer Taking Androgen Deprivation Therapy

Study acronym: GAINPCCONTROL
StatusActive, Not Recruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 1 year 3 months later Jul 31, 2026 → Oct 31, 2027
See other at-risk trials from Hamilton Health Sciences Corporation

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion pushed from Jul 31, 2026 to Oct 31, 2027
    • Enrollment closed, study ongoing
    • Site details revised
    v3
  2. Trial status: Not Yet Recruiting to Recruitingv2 Show 4 more changesShow less
    • Start date changed from estimate of Apr 1, 2025 to Jul 2, 2025
    • Primary and study completion dates: Mar 31, 2026 to Jul 31, 2026
    • Site details revised
    • Study description expanded, about 2 words
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
GAIN PC CONTROL is a study investigating Glucagon-Like Peptide-1 Receptor Agonists in men with prostate cancer who are being treated with androgen deprivation therapy.
Trial Details
NCT Number NCT06908694
Lead Sponsor Hamilton Health Sciences Corporation
Collaborators: McMaster University
Conditions
(from sponsor)		 Prostate Cancer
Related terms Prostatic Neoplasms
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov